Advertisement

 

 

Dapsone-associated fixed drug eruption.

Dapsone-associated fixed drug eruption.
Author Information (click to view)

Garcia D, Cohen PR,


Garcia D, Cohen PR, (click to view)

Garcia D, Cohen PR,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of clinical pharmacology 2017 04 2810(7) 717-725 doi 10.1080/17512433.2017.1322508
Abstract
INTRODUCTION
Dapsone is a sulfone drug used to treat infectious conditions and also numerous dermatologic diseases. Fixed drug eruption is a distinctive adverse cutaneous reaction associated with the initial administration and subsequent delivery of a specific agent. Areas covered: The authors preformed a literature search using the following keywords: dapsone, fixed drug eruption, and adverse cutaneous drug reaction. Bibliographies were also reviewed for pertinent articles. The results were combed for relevant papers and reviewed. Articles pertaining to dapsone-associated fixed drug eruption were included. Expert commentary: The majority of cases of dapsone-associated fixed drug eruption in the literature come from Africa or India where there is a high prevalence of patients treated for leprosy. Characteristics of these cases are similar to fixed drug eruption described in the western literature, with differences in frequency of multiple versus solitary lesions. Dapsone-associated fixed drug eruption should be considered when reviewing the drug history of a patient with fixed drug eruption. In the case of darker pigmented individuals, multiple fixed drug eruption lesions may be more common. Multiple lesions may mimic Kaposi’s sarcoma in human immunodeficiency virus positive patients. Dapsone-associated fixed drug eruption should be considered in the differential diagnosis of multiple hyperpigmented lesions.

Submit a Comment

Your email address will not be published. Required fields are marked *

1 × 2 =

[ HIDE/SHOW ]